Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Monday, 03'rd Feb 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Buy, Sell, Or Hold ABBV Stock At $185?
09:25am, Monday, 03'rd Feb 2025
AbbVie (NYSE: ABBV) recently released its Q4 results, with revenues and earnings comfortably above the street estimates. It reported sales of $15.1 billion and adjusted earnings of $2.16 per share, co
2 Undervalued Dividend Stocks Ready For A Major Comeback
07:30am, Sunday, 02'nd Feb 2025
The economy is mixed - strong in some sectors, weak in others. I see value in cyclical stocks and healthcare, both lagging but poised for growth. One pick is a cyclical turnaround story with strong re
Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.
06:05am, Saturday, 01'st Feb 2025
Many people set a goal to save $1 million for retirement. This amount may or may not be sufficient in today's economy, but it's at least a good start.
AbbVie Q4 Earnings: Strong Revenue Results, Ambitious Forecasts - A Buy With Caveats
04:39pm, Friday, 31'st Jan 2025
AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's guidance
AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds
02:52pm, Friday, 31'st Jan 2025
AbbVie Inc. reported strong Q4 2024 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care, and this offset worse-than-expected Humira erosion. 2025 guidance includes $59 billion in r
AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs
02:25pm, Friday, 31'st Jan 2025
ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to more than $31 billion.
Why AbbVie Stock Is Jumping Today
12:42pm, Friday, 31'st Jan 2025
Shares of AbbVie (ABBV 6.98%) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day.
AbbVie Inc. (ABBV) Q4 2024 Earnings Call Transcript
12:26pm, Friday, 31'st Jan 2025
AbbVie Inc. (NYSE:ABBV ) Q4 2024 Earnings Conference Call January 31, 2025 9:00 AM ET Company Participants Liz Shea - Senior Vice President, Investor Relations Rob Michael - Chief Executive Officer Je
PCE Inflation Increased In Line With Expectation
11:47am, Friday, 31'st Jan 2025
Today's pre-market activity is positive, with futures in the green across major indexes: the Dow is +110 points at this hour, with the S&P 500 +26 and the Nasdaq leading the way, +158 points. The smal
December PCE Steady with Expectations; Plenty of Mixed Q4 Earnings
11:26am, Friday, 31'st Jan 2025
PCE results were as in-line with expectations as one could expect: +0.3% on headline month over month, +2.6% year over year.
AbbVie shares rise as new drug sales offset Humira decline in Q4
10:59am, Friday, 31'st Jan 2025
Abbvie Inc (NYSE:ABBV) shares surged after the company posted a positive financial report for the fourth quarter, with sales growth of newer drugs offsetting a steep decline in Humira revenue. Earn
AbbVie Investors Trigger Trend-Following Signal: Time to Load Up
10:51am, Friday, 31'st Jan 2025
AbbVie NYSE: ABBV is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira's patent cliff are behind it, w
AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook
10:41am, Friday, 31'st Jan 2025
AbbVie (ABBV) stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm posted better-than-expected sales and gave strong guidance on higher demand for two of its drugs to tre
Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics
10:31am, Friday, 31'st Jan 2025
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stree
